A detailed history of Quinn Opportunity Partners LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 26,624 shares of BLUE stock, worth $203,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,624
Previous 26,624 -0.0%
Holding current value
$203,939
Previous $26,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$2.79 - $5.03 $48,825 - $88,025
-17,500 Reduced 39.66%
26,624 $87,000
Q4 2022

Feb 14, 2023

BUY
$5.77 - $8.49 $254,595 - $374,612
44,124 New
44,124 $305,000
Q3 2022

Nov 14, 2022

SELL
$3.75 - $7.39 $57,750 - $113,806
-15,400 Reduced 25.87%
44,124 $279,000
Q2 2022

Aug 15, 2022

SELL
$2.94 - $5.23 $239,022 - $425,199
-81,300 Reduced 57.73%
59,524 $246,000
Q1 2022

May 16, 2022

SELL
$4.07 - $10.6 $40,700 - $106,000
-10,000 Reduced 6.63%
140,824 $683,000
Q4 2021

Feb 14, 2022

SELL
$8.96 - $16.31 $710,312 - $1.29 Million
-79,276 Reduced 34.45%
150,824 $1.51 Million
Q3 2021

Nov 15, 2021

BUY
$11.24 - $21.0 $169,724 - $317,100
15,100 Added 7.02%
230,100 $4.4 Million
Q2 2021

Aug 16, 2021

SELL
$18.04 - $22.09 $414,920 - $508,070
-23,000 Reduced 9.66%
215,000 $6.88 Million
Q1 2021

May 13, 2021

BUY
$16.59 - $33.89 $3.95 Million - $8.07 Million
238,000 New
238,000 $7.18 Million
Q1 2018

May 14, 2018

SELL
$105.8 - $150.94 $137,540 - $196,222
-1,300 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$81.25 - $130.7 $105,625 - $169,909
1,300
1,300 $232,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $591M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Quinn Opportunity Partners LLC Portfolio

Follow Quinn Opportunity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quinn Opportunity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quinn Opportunity Partners LLC with notifications on news.